Monomethyl Fumarate
Autoimmune Hepatitis
West China HospitalSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Autoimmune Hepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azathioprine Xiaoli Fan | Phase 4 | BB |
Jkb-122 TaiwanJ Pharmaceuticals Co., Ltd | Phase 2 | CCC |
Benadryl Elizabeth C. Verna | Phase 1 | CC |
Solu-Cortef Elizabeth C. Verna | Phase 1 | CC |
Siplizumab Elizabeth C. Verna | Phase 1 | C |
METRONIDAZOLE Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A | D |
Budesonide Mayo Clinic | N/A | D |
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →